Cargando…

Stem Cell Markers SOX-2 and OCT-4 Enable to Resolve the Diagnostic Dilemma between Ameloblastic Carcinoma and Aggressive Solid Multicystic Ameloblastoma

BACKGROUND: Ameloblastic carcinoma (ACA) is a malignant neoplasm with overlapping histopathological features of benign aggressive solid multicystic ameloblastoma (SMA). This often leads to misdiagnosis with direct implication on the management protocol. The need of the hour is to adopt reliable tiss...

Descripción completa

Detalles Bibliográficos
Autores principales: Khan, Wafa, Augustine, Dominic, Rao, Roopa S, Sowmya, Samudrala Venkatesiah, Haragannavar, Vanishri C, Nambiar, Shwetha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282489/
https://www.ncbi.nlm.nih.gov/pubmed/30596059
http://dx.doi.org/10.4103/abr.abr_135_18
_version_ 1783379004822126592
author Khan, Wafa
Augustine, Dominic
Rao, Roopa S
Sowmya, Samudrala Venkatesiah
Haragannavar, Vanishri C
Nambiar, Shwetha
author_facet Khan, Wafa
Augustine, Dominic
Rao, Roopa S
Sowmya, Samudrala Venkatesiah
Haragannavar, Vanishri C
Nambiar, Shwetha
author_sort Khan, Wafa
collection PubMed
description BACKGROUND: Ameloblastic carcinoma (ACA) is a malignant neoplasm with overlapping histopathological features of benign aggressive solid multicystic ameloblastoma (SMA). This often leads to misdiagnosis with direct implication on the management protocol. The need of the hour is to adopt reliable tissue biomarkers to differentiate these lesions accurately that will help to implement an appropriate treatment modality. Few studies to differentiate ACA and SMA in literature with a limitation of a single marker and lack of availability of cases have prompted us to undertake this study. Thereby, this study is aimed at resolving the diagnostic dilemma in differentiating ACA and aggressive SMA using SOX-2, OCT-4 and CD44. MATERIALS AND METHODS: Tissue samples involved 40 archival cases of histopathologically confirmed cases of ACA (n = 20) and SMA (n = 20). The sections were subjected to immunohistochemical staining using antibodies to SOX-2, OCT-4 and CD44. Nuclear staining for SOX-2 and OCT-4 and membranous reactivity for CD44 was considered positive. RESULTS: The expression of SOX-2 and OCT-4 in ACA was statistically significant when compared to SMA (P < 0.001). CD44 showed an insignificant statistical value of <0.077 in differentiating ACA and SMA. SOX-2 and OCT-4 expression in ACA showed a significant correlation coefficient of 0.616 at P < 0.004. CONCLUSIONS: SOX-2 and OCT-4 could serve as independent novel markers in resolving the diagnostic dilemma between ACA and aggressive SMA.
format Online
Article
Text
id pubmed-6282489
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-62824892018-12-28 Stem Cell Markers SOX-2 and OCT-4 Enable to Resolve the Diagnostic Dilemma between Ameloblastic Carcinoma and Aggressive Solid Multicystic Ameloblastoma Khan, Wafa Augustine, Dominic Rao, Roopa S Sowmya, Samudrala Venkatesiah Haragannavar, Vanishri C Nambiar, Shwetha Adv Biomed Res Original Article BACKGROUND: Ameloblastic carcinoma (ACA) is a malignant neoplasm with overlapping histopathological features of benign aggressive solid multicystic ameloblastoma (SMA). This often leads to misdiagnosis with direct implication on the management protocol. The need of the hour is to adopt reliable tissue biomarkers to differentiate these lesions accurately that will help to implement an appropriate treatment modality. Few studies to differentiate ACA and SMA in literature with a limitation of a single marker and lack of availability of cases have prompted us to undertake this study. Thereby, this study is aimed at resolving the diagnostic dilemma in differentiating ACA and aggressive SMA using SOX-2, OCT-4 and CD44. MATERIALS AND METHODS: Tissue samples involved 40 archival cases of histopathologically confirmed cases of ACA (n = 20) and SMA (n = 20). The sections were subjected to immunohistochemical staining using antibodies to SOX-2, OCT-4 and CD44. Nuclear staining for SOX-2 and OCT-4 and membranous reactivity for CD44 was considered positive. RESULTS: The expression of SOX-2 and OCT-4 in ACA was statistically significant when compared to SMA (P < 0.001). CD44 showed an insignificant statistical value of <0.077 in differentiating ACA and SMA. SOX-2 and OCT-4 expression in ACA showed a significant correlation coefficient of 0.616 at P < 0.004. CONCLUSIONS: SOX-2 and OCT-4 could serve as independent novel markers in resolving the diagnostic dilemma between ACA and aggressive SMA. Medknow Publications & Media Pvt Ltd 2018-11-28 /pmc/articles/PMC6282489/ /pubmed/30596059 http://dx.doi.org/10.4103/abr.abr_135_18 Text en Copyright: © 2018 Advanced Biomedical Research http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Original Article
Khan, Wafa
Augustine, Dominic
Rao, Roopa S
Sowmya, Samudrala Venkatesiah
Haragannavar, Vanishri C
Nambiar, Shwetha
Stem Cell Markers SOX-2 and OCT-4 Enable to Resolve the Diagnostic Dilemma between Ameloblastic Carcinoma and Aggressive Solid Multicystic Ameloblastoma
title Stem Cell Markers SOX-2 and OCT-4 Enable to Resolve the Diagnostic Dilemma between Ameloblastic Carcinoma and Aggressive Solid Multicystic Ameloblastoma
title_full Stem Cell Markers SOX-2 and OCT-4 Enable to Resolve the Diagnostic Dilemma between Ameloblastic Carcinoma and Aggressive Solid Multicystic Ameloblastoma
title_fullStr Stem Cell Markers SOX-2 and OCT-4 Enable to Resolve the Diagnostic Dilemma between Ameloblastic Carcinoma and Aggressive Solid Multicystic Ameloblastoma
title_full_unstemmed Stem Cell Markers SOX-2 and OCT-4 Enable to Resolve the Diagnostic Dilemma between Ameloblastic Carcinoma and Aggressive Solid Multicystic Ameloblastoma
title_short Stem Cell Markers SOX-2 and OCT-4 Enable to Resolve the Diagnostic Dilemma between Ameloblastic Carcinoma and Aggressive Solid Multicystic Ameloblastoma
title_sort stem cell markers sox-2 and oct-4 enable to resolve the diagnostic dilemma between ameloblastic carcinoma and aggressive solid multicystic ameloblastoma
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282489/
https://www.ncbi.nlm.nih.gov/pubmed/30596059
http://dx.doi.org/10.4103/abr.abr_135_18
work_keys_str_mv AT khanwafa stemcellmarkerssox2andoct4enabletoresolvethediagnosticdilemmabetweenameloblasticcarcinomaandaggressivesolidmulticysticameloblastoma
AT augustinedominic stemcellmarkerssox2andoct4enabletoresolvethediagnosticdilemmabetweenameloblasticcarcinomaandaggressivesolidmulticysticameloblastoma
AT raoroopas stemcellmarkerssox2andoct4enabletoresolvethediagnosticdilemmabetweenameloblasticcarcinomaandaggressivesolidmulticysticameloblastoma
AT sowmyasamudralavenkatesiah stemcellmarkerssox2andoct4enabletoresolvethediagnosticdilemmabetweenameloblasticcarcinomaandaggressivesolidmulticysticameloblastoma
AT haragannavarvanishric stemcellmarkerssox2andoct4enabletoresolvethediagnosticdilemmabetweenameloblasticcarcinomaandaggressivesolidmulticysticameloblastoma
AT nambiarshwetha stemcellmarkerssox2andoct4enabletoresolvethediagnosticdilemmabetweenameloblasticcarcinomaandaggressivesolidmulticysticameloblastoma